Similar articles

• Mazindol and growth hormone inhibition in Duchenne muscular dystrophy.

  Zatz M, Vainzof M, Rapaport D, da Rocha JM, Pavanello Rde C, Betti RT. Zatz M, et al. Am J Med Genet. 1987 Aug;27(4):993-5. doi: 10.1002/ajmg.1320270433. Am J Med Genet. 1987. PMID: 3321999 Clinical Trial. No abstract available.
• Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency.

  Zatz M, Betti RT, Levy JA. Zatz M, et al. Am J Med Genet. 1981;10(3):301-4. doi: 10.1002/ajmg.1320100313. Am J Med Genet. 1981. PMID: 7304674 No abstract available.
• Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up.

  Zatz M, Betti RT. Zatz M, et al. Am J Med Genet. 1986 Jul;24(3):567-72. doi: 10.1002/ajmg.1320240323. Am J Med Genet. 1986. PMID: 3728575 No abstract available.
• [Chronologic study of signs of myocardiopathy in progressive muscular dystrophy].

  Barona Zamora P, Narbona García J, Alvarez Gómez MJ, Fidalgo Andrés ML, Sáenz de Buruaga J, Villa Elizaga I. Barona Zamora P, et al. An Esp Pediatr. 1993 Feb;38(2):173-7. An Esp Pediatr. 1993. PMID: 8439105 Review. Spanish.
• Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders.

  English KM, Gibbs JL. English KM, et al. Dev Med Child Neurol. 2006 Mar;48(3):231-5. doi: 10.1017/S0012162206000491. Dev Med Child Neurol. 2006. PMID: 16483403 Review.